Biologics

The global spinal biologics market is expected to reach $2.4 billion by 2020, according to a MarketsandMarkets report. Here are eight companies leading the spinal biologics field.

Adam W. Anz, MD, is an orthopedic surgeon and sports medicine specialist at Gulf Breeze, Fla.-based Andrews Institute for Orthopaedics & Sports Medicine. He is the director of the Andrews Institute Regenerative Medicine Center and oversees the ATC Fellowship Program…

RTI Surgical accomplished a major milestone in April.

Here are 14 developments in spinal biologics in 2018 so far.

Patients who received intradiscal injections of SpinalCyte's new cell-based therapy CybroCell showed significantly improved disc height after six months.

Regenerative medicine company Mesoblast completed enrollment for its Phase 3 mesenchymal cell therapy trial to treat chronic low back pain due to degenerative disc disease.

The global orthobiologics market is predicted to exceed $5.52 billion in 2019, according to Transparency Market Research.

DiscGenics presented results from two preclinical studies assessing its IDCT product, a homologous, allogenic, injectable cell therapy.

Three spine surgeons from across the U.S. discuss where they see the biggest opportunities in spinal biologics and disc generation.

Aziyo Biologics launched OsteGro, an allograft bone matrix designed to support new bone growth in procedures such as hip reconstruction, bone fracture repair and spinal fusion.